Full Press Release Details
NEW BRUNSWICK, N.J. , Jan. 26, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) and Actelion Ltd. (SIX: ATLN) will host a conference call for investors at 8:00 a.m. (Eastern Time) on Thursday, Jan. 26 th , to discuss the announcement that they have entered into a definitive agreement for Johnson & Johnson to acquire Actelion Ltd for $30 billion with a spin-out of a new R&D company.
The call will include the following participants:
Johnson & Johnson: Alex Gorsky , Chairman and Chief Executive Officer| Dominic Caruso , Executive Vice President, Chief Financial Officer Dr. Paul Stoffels , Chief Scientific Officer Joaquin Duato , Executive Vice President, Worldwide Chairman, Pharmaceuticals Joseph J. Wolk, Vice President of Investor Relations
Actelion: Jean-Pierre Garnier , Chairman Dr. Jean-Paul Clozel, CEO and co-founder
Investors and other interested parties can access the webcast/conference call in the following ways:
About Johnson & Johnson Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 126,900 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.
SOURCE Johnson & Johnson